We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
-7.05%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.34B
AUM Growth
+$132M
Cap. Flow
+$289M
Cap. Flow %
21.59%
Top 10 Hldgs %
54.87%
Holding
79
New
21
Increased
28
Reduced
5
Closed
19

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$72.2M
2
EXAS
Exact Sciences
EXAS
+$45.4M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$44M
4
JANX icon
Janux Therapeutics
JANX
+$34M
5
ACLX
Arcellx
ACLX
+$31.3M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$97.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$52.3M
3
AZN icon
AstraZeneca
AZN
+$27.1M
4
NARI
Inari Medical, Inc. Common Stock
NARI
+$19.9M
5
ARGX icon
argenx
ARGX
+$19.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
76
TG Therapeutics
TGTX
$7.64B
– –
-1,050,000
Closed -$16M
VKTX icon
77
Viking Therapeutics
VKTX
$3.88B
– –
-75,000
Closed -$6.15M
SWAV
78
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-25,000
Closed -$8.14M
ALPN
79
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-350,000
Closed -$13.9M
1 2 3
4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Vestal Point Capital held 79 positions worth $1.34B, up 11% from $1.21B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Vestal Point Capital deployed $289M of net new capital in Q2 2024, opening 21 new positions and adding to 28 existing holdings. Its largest new stake was Janux Therapeutics: 725,000 shares worth $30.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Inari Medical, Inc. Common Stock, an estimated $19.9M trimmed.

  • Vestal Point Capital's largest Q2 2024 buy was Janux Therapeutics: 725,000 shares worth $30.4M.
  • Vestal Point Capital added most to Ultragenyx Pharmaceutical in Q2 2024, an estimated $72.2M increase.
  • Vestal Point Capital's biggest Q2 2024 reduction was Inari Medical, Inc. Common Stock, cutting an estimated $19.9M.
  • Vestal Point Capital fully exited Neurocrine Biosciences in Q2 2024, selling an estimated $97.9M.
  • Vestal Point Capital's ten largest holdings make up 55% of its $1.34B portfolio in Q2 2024.
  • Vestal Point Capital opened 21 new positions and closed 19 in Q2 2024.
  • Vestal Point Capital's portfolio value rose 11% quarter-over-quarter to $1.34B.

Based on Vestal Point Capital's 13F filing for Q2 2024, filed 14 Aug 2024.